65. Chien Liu, op. cit., p. 275.

  

66. C. H. Stuart-Harris, G. C. Schild, op. cit., p. 203.

  

67. Ibid., p. 164.

  

68. Ibid., p. 150.

  

69. J. Salk and D. Salk, "Control of Influenza and Poliomyelitis With Killed Virus Vaccines," Science, Vol. 195, 4 March 1977, p. 842.

  

70. J. W. F. Smith. "Vaccination Strategy," in P. Selby, op. cit., pp. 277-78.

  

71. Ibid., p. 278.

  

72. C. H. Stuart-Harris, G. C. Schild, op. cit., pp. 185-193.

  

73. D. A. J. Tyrrell, "Inactivated Whole Virus Vaccine," in p. Selby, op. cit., pp. 137-140.

  

74. E. D. Kilbourne, "Future Influenza Vaccines and the Use of Genetic Recombinants," Bulletin of the World Health Organization, Vol. 41, 1969, p.643.

  

75. H. B. Dull and W. R. Dowdle, "Influenza," in P. E. Sartwell (editor), Marcy-Roseman's Preventive Medicine and Public Health, 10 ed., Appleton-Century-Crofts, New York, 1973, p. 74.

  

76. W. I. B. Beveridge, op. cit., p. 95.

  

77. J. W. G. Smith, "Vaccination Strategy," in P. Selby, op. cit., p. 280. ,

  

78. C. H. Stuart-Harris, G. C. Schild, op. cit., pp. 148-159.

  

79. H. B. Dull and W. R. Dowdle, "Influenza," in P. F. Sartwell, op. cit., p. 72.

  

80. C. H. Stuart-Harris, G. C. Schild, op. cit., 175-6.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement